Effects of Fibrates in Kidney Disease
Authors:
- Min JunMJMin Jun
- Bin ZhuBZBin Zhu
- Marcello TonelliMTMarcello Tonelli
- Meg J. JardineMJMeg J. Jardine
- Anushka PatelAPAnushka Patel
- Bruce NealBruce Neal
- Thaminda LiyanageTLThaminda Liyanage
- Anthony KeechAKAnthony Keech
- Alan CassACAlan Cass
- Vlado PerkovicVPVlado Perkovic
- 1 November 2012
- Vol. 60 (20) , 2061-2071
Abstract
No abstract availableKeywords
Funding Information
- Australian National Health and Medical Research Council (571281, 512657)
- CSL Limited
- Australian Food and Grocery Council
- Bupa Australia
- Johnson and Johnson
- Merck Schering Plough
- Roche
- Servier
- United Healthcare Group
- Roche Diagnostics
- Solvay
- Abbott
- Merck
- Sanofi-Aventis
- Baxter
- Servier
- Gambro
- Baxter
- Johnson and Johnson
- Novartis
- Roche
- Servier
This publication has 42 references indexed in Scilit:
- Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic ParticipantsDiabetes Care, 2012
- Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal ImpairmentDiabetes Care, 2012
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysisThe Lancet, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Comparison of the Prevalence and Mortality Risk of CKD in Australia Using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR Estimating Equations: The AusDiab (Australian Diabetes, Obesity and Lifestyle) StudyAmerican Journal of Kidney Diseases, 2010
- Lowering Blood Pressure Reduces Renal Events in Type 2 DiabetesJournal of the American Society of Nephrology, 2009
- Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiencyKidney International, 2004
- Predictors of New-Onset Kidney Disease in a Community-Based PopulationJAMA, 2004
- Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities StudyKidney International, 2000